Filing Flows › Corcept Therapeutics (CORT) › Free cash flow
Corcept Therapeutics (CORT) free cash flow by quarter
Corcept Therapeutics' free cash flow was $142M in Q3 2026 (third quarter 2026), +358% from Q2 2026. Over the last 5 quarters it ranged from $5.0M (Q1 2025) to $142M (Q3 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $142M | +358% | — |
| Q2 2026 | $31.0M | -19% | -29% |
| Q4 2025 | $38.4M | -12% | — |
| Q2 2025 | $43.9M | +773% | — |
| Q1 2025 | $5.0M | — | — |
Q3 2026 at a glance
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Questions
What is Corcept Therapeutics' free cash flow?
Corcept Therapeutics' free cash flow was $142M in Q3 2026 (third quarter 2026), +358% from Q2 2026.
How has Corcept Therapeutics' free cash flow changed?
Over the last 5 quarters it ranged from $5.0M (Q1 2025) to $142M (Q3 2026).